Targeted regulation of the FTO gene containing this mutation site can effectively reduce the risk of NAFLD in people with FTO gene mutation and is expected to become a valuable new therapeutic target. The gene discussed is FTO; the disease is metabolic dysfunction-associated steatotic liver disease.